---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-23-000019"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:25:51.045423+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q4 revenue up 10% to $139M; net loss narrows to $23M; issues 2023 guidance with improved EBITDA

## Summary
- Q4 revenue $139M (+10% YoY); full year revenue $510M (+5% YoY).
- Q4 net loss $23M vs $42M loss in Q4 2021; full year net loss $144M vs $8M loss in 2021 (2021 included $109M Inivata gain).
- Q4 adjusted EBITDA -$1.2M vs -$10M in Q4 2021; full year adjusted EBITDA -$48M vs -$4M in 2021.
- 2023 guidance: revenue $545-555M (7-9% growth), adjusted EBITDA $(27)-$(22)M (44-54% improvement).
- Cash and marketable securities $438M at quarter end.

## SEC filing metadata
- accession: 0001077183-23-000019
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/neo-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-23-000019
- JSON: https://secwatch.observer/filing/0001077183-23-000019.json
- Plain text: https://secwatch.observer/filing/0001077183-23-000019.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported full year ended December 31, 2022 results: revenue $510 million, net income $144 million. Guidance initiated.
  - Period: full year ended December 31, 2022
  - Revenue: $510 million
  - Net income: $144 million
  - Guidance: initiated
  - Result: reported results
  source text: Consolidated revenue for 2022 was $510 million, an increase of 5% over 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm
- Earnings Releases
  NEOGENOMICS INC reported the fourth quarter of 2022 results: revenue $139 million, net income $23 million. Guidance initiated.
  - Period: the fourth quarter of 2022
  - Revenue: $139 million
  - Net income: $23 million
  - Guidance: initiated
  - Result: reported results
  source text: Consolidated revenue for the fourth quarter of 2022 was $139 million, an increase of 10% over the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.